DCVC

Activity from announced rounds

Activity in this selectionOct 21, 2026 · Sep 22, 2026

DCVC is an investment firm identified by TypeSafe AI as an existing investor and by its own communications as a backer of Shennon Biotechnologies.

Recorded funding activity

TypeSafe turns unstructured inputs into typed decisions and probability scores for automated software. Shennon develops T-cell engager therapies for solid tumors. Separate TypeSafe financings remain separate events under one investor history.

Sources
Rounds participated in
2
Confirmed lead rounds
1
All roles disclosed
New companies
1
First participation on record · 1 follow-on
Funding in participating rounds
$870M
1 disclosed · full round size, not this investor’s share

By stage

Series A2

By primary sector

AI1
Hardware1

By country

United Kingdom1
United States1

Rounds

2 in this selection
TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$870MSeries A
Participant
Universal Quantum

Modular trapped-ion quantum computers built by connecting small quantum chips.

>$100MSeries A
Lead